Founded in Palo Alto, California in 1996, Vivo Capital is a leading global healthcare investment firm with a multi-fund investment platform in venture capital, growth equity, buyout, and public equities.

Vivo’s Three Fund Vehicles

Private Equity

Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation. Our private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. We invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.

Public Equity

Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.

Venture Capital

Vivo Innovation Fund (i.e., Vivo PANDA Fund) focuses on investing in venture stage companies with the potential to develop game changing healthcare technologies or products. The fund typically invests in early stage (i.e. Series A) financing rounds.

Our Team

Our Portfolio


Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Go to Top